Joseph Shulman Sells 1,228 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) insider Joseph Shulman sold 1,228 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $70,266.16. Following the completion of the transaction, the insider now owns 8,509 shares of the company’s stock, valued at $486,884.98. This trade represents a 12.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Joseph Shulman also recently made the following trade(s):

• On Tuesday, February 11th, Joseph Shulman sold 794 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $57.51, for a total transaction of $45,662.94.
• On Tuesday, February 4th, Joseph Shulman sold 1,281 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $59.43, for a total transaction of $76,129.83.

Rhythm Pharmaceuticals Stock Down 0.4 %

RYTM opened at $57.74 on Friday. The company has a fifty day moving average price of $57.10 and a two-hundred day moving average price of $53.89. Rhythm Pharmaceuticals, Inc. has a 52 week low of $35.17 and a 52 week high of $68.58.

Institutional Trading of Rhythm Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. SRS Capital Advisors Inc. grew its holdings in Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after acquiring an additional 400 shares during the period. Raleigh Capital Management Inc. acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter worth $28,000. SBI Securities Co. Ltd. acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter worth $37,000. R Squared Ltd acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter worth $44,000. Finally, State of Wyoming acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter worth $61,000.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 target price on shares of Rhythm Pharmaceuticals in a research note on Wednesday. Canaccord Genuity Group reiterated a “buy” rating and issued a $80.00 target price on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and issued a $69.00 target price on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. Oppenheimer began coverage on shares of Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an “outperform” rating and a $76.00 price objective for the company. Finally, Jefferies Financial Group began coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They issued a “buy” rating and a $80.00 price objective for the company. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $68.09.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.